Immuneering Corporation's stock is experiencing a decline today, despite the company announcing a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer. The update, released on January 13, 2025, highlighted two additional partial responses, bringing the overall response rate to 50% among evaluable patients, which is significantly higher than the historical benchmark of 32% for FOLFIRINOX alone. Additionally, Immuneering strengthened its cash position by raising nearly $14 million through its ATM facility, aiming to sustain momentum with further data updates and trial initiations planned for 2025.
Despite these positive developments, Immuneering Corporation (IMRX) is trading at $1.99, down 1.00% from the previous close of $2.01 as of 10:00 AM on January 14. The stock opened at $2.07 and has seen a low of $1.97 today. With a volume of 146,223 shares, representing only 6.05% of the average daily volume of 2,415,745, the trading activity is relatively low, which is typical for this early in the trading day.